An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).

Starting soon · Early Phase 1

Conditions studied: Multiple Sclerosis

In brief

This is an Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined with NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).

Key facts

Study ID

NCT07546110

Run by

The Affiliated Hospital of Xuzhou Medical University

People needed

20

Starts

2026-05-01

Expected to finish

2028-12-30

Last updated by the study team

2026-04-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.